Valeo Pharma
Valeo Pharma is a Canadian specialty pharmaceutical company that licenses and commercializes innovative prescription drugs across respiratory, ophthalmology, and specialty therapeutic areas in Canada, serving physicians and patients through a dedicated national field sales force and pharmacy distribution.
- Company typePublic
- Founded2003
- HeadquartersKirkland, Canada
- Headcount51–100
- GTM typeB2B
- OfferingHardware or Manufacturing
What Valeo Pharma does
Valeo Pharma Inc. is a publicly traded Canadian specialty pharmaceutical company headquartered in Kirkland, Quebec, that licenses and acquires Canadian commercial rights to innovative, commercial-stage prescription drugs from international pharmaceutical partners. The company operates dedicated business units across three primary therapeutic areas — Respiratory/Allergy, Ophthalmology, and Specialty Products — with an additional focus on Neurology (Onstryv/safinamide for Parkinson's disease) and Oncology. Its portfolio of 12 commercialized products includes Enerzair Breezhaler and Atectura Breezhaler (asthma therapies), Redesca/Redesca HP (a low molecular weight heparin biosimilar with over 50% Canadian market share), Xiidra and Simbrinza (ophthalmology, licensed from Novartis), Allerject (epinephrine auto-injector, licensed from Kaléo), and Onstryv. Products are acquired through licensing and supply agreements rather than internal R&D, with key partners including Novartis Pharmaceuticals Canada (7-year agreement signed July 2022), Kaléo Inc., and previously Veru Inc. (agreement mutually terminated May 2023).
The company's commercialization model relies on a dedicated field sales force and marketing team that engages Canadian physicians directly across general practice and specialty channels, supported by a business-unit structure per therapeutic area. Revenue is generated through product sales to Canadian pharmacies and healthcare providers, with pricing substantially determined by provincial drug reimbursement programs including Quebec's RAMQ, the Ontario Drug Benefit Program, Manitoba Pharmacare, the Saskatchewan Drug Plan, the BC Ministry of Health, and federal NIHB and VAC programs. Valeo reported record fiscal 2023 (year ended October 31, 2023) revenues of $54 million CAD, up 94% over $27.7 million in fiscal 2022, with adjusted gross profit of $16.9 million (+80% YoY) but an adjusted EBITDA loss of $10.9 million reflecting continued investment in commercialization, sales infrastructure, and new product launches.
The company listed on the Toronto Stock Exchange (VPH) in March 2022 and has funded its growth through a US$30 million secured term loan from Sagard Healthcare Partners (July 2022), a $4.5 million private placement led by Investissement Québec (August 2023), and a $5 million credit facility from Accord Financial (September 2023). Leadership was strengthened in 2023 with the appointments of Pascal Tougas as CFO (replacing Luc Mainville) and board additions including former Bausch Health Canada and Alcon Canada presidents. The company also announced organizational changes and cost reduction initiatives in November 2023 targeting more than $2 million in annual savings.
Valeo Pharma firmographics
Firmographics- Name
- Valeo Pharma
- Legal name
- Valeo Pharma Inc.
- Website
- https://valeopharma.com
- Company type
- Public
- Founded year
- 2003
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- Valeo Pharma is a Canadian specialty pharmaceutical company that licenses and commercializes innovative prescription drugs across respiratory, ophthalmology, and specialty therapeutic areas in Canada, serving physicians and patients through a dedicated national field sales force and pharmacy distribution.
- Ownership category
- akta.pro rank
Valeo Pharma industry classification
Industry- Product category
- Specialty Pharmaceuticals
- NAICS
- Drugs and Druggists' Sundries Merchant Wholesalers (424210)
- SIC
- Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)
- akta.pro primary industry
- Specialty Pharmaceutical Distributors (HLAIAJAB)
- akta.pro secondary industries
- Respiratory & Allergy Pharmaceuticals (HLAIAAAH), Prescription Pharmaceutical (Rx) Wholesale Distribution (CRAOAHAA)
Keywords
Where Valeo Pharma is headquartered
LocationHeadquarters
- HQ city
- Kirkland
- HQ country
- Canada
- HQ region
- North America
Offices1 record
Markets served
Valeo Pharma business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Supply Chain, Personnel, Marketing or Sales, Operations
Revenue model
- Pharmaceutical Product Sales: Valeo Pharma generates revenue through the sale of commercialized prescription pharmaceutical products including Enerzair, Atectura, Redesca, Xiidra, Simbrinza, Allerject, and Onstryv across therapeutic areas of respiratory/allergy, ophthalmology, and specialty products.
- Working Capital and Growth Financing: The company secured a $5 million credit facility with Accord Financial Inc. and completed a $4.5 million private placement financing to support working capital and growth initiatives.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Transaction based/ take rate | Pay-as-you-go | Prescription pharmaceutical products sold through pharmacies and healthcare providers |
Go-to-market motion2 records
Distribution channels1 record
Marketing channels4 records
Valeo Pharma product offering
Product offeringCore offering
Valeo Pharma is a Canadian specialty pharmaceutical company that licenses and acquires Canadian commercial rights to innovative, proprietary prescription drugs from international pharmaceutical partners, and commercializes them through its own field sales force, marketing teams, and dedicated business units in respiratory/allergy, ophthalmology, and specialty therapeutic areas. The company's portfolio consists of 12 commercialized products, including Enerzair, Atectura, Redesca, Xiidra, Simbrinza, Allerject, and Onstryv.
Product overview
Valeo Pharma is a Canadian pharmaceutical company commercializing innovative prescription products across five therapeutic areas: Respiratory/Allergy, Ophthalmology, Specialty Products, Neurology, and Oncology. The company's portfolio consists of 12 commercialized products including core brands Enerzair Breezehaler and Atectura Breezhaler (asthma therapies), Redesca (anticoagulant biosimilar), Xiidra and Simbrinza (ophthalmology), Allerject (epinephrine auto-injector), and Onstryv (Parkinson's disease treatment). Products are acquired through licensing and partnership agreements with international pharmaceutical companies and commercialized in the Canadian market. The company operates a focused commercial model with dedicated business units for each therapeutic area.
Differentiator
Problem solved
Functional benefit
Products and services
- Enerzair Breezhaler Innovative single maintenance and reliever asthma therapy (triple-active) commercialized in Canada through the Breezhaler inhaler device. Marketed as a leading drug in Canada's fast-growing triple-active asthma market, promoted through dedicated physician engagement programs.
- Atectura Breezhaler Respiratory therapy for asthma management, used as an asthma control medication for patients requiring additional treatment options. Commercialized in Canada through the Breezhaler inhaler device.
- Redesca / Redesca HP Low molecular weight heparin (LMWH) biosimilar anticoagulant for Canadian patients. Leads the LMWH biosimilar market in Canada with more than 50% market share. Available in standard and HP (high potency) presentations.
- Xiidra Prescription eye drop solution indicated for the treatment of the signs and symptoms of dry eye disease. Ophthalmology product acquired through partnership with Novartis for Canadian commercialization.
- Simbrinza Prescription ophthalmology therapy for the treatment of eye conditions such as glaucoma. Acquired through a 7-year Commercialization and Supply Agreement with Novartis Pharmaceuticals Canada Inc. for the Canadian market.
- Allerject Epinephrine injection, USP auto-injector for the emergency treatment of serious allergic reactions including anaphylaxis. Commercialized in Canada under a license from Kaléo Inc., with promotional launch activities in April 2023.
- Onstryv (safinamide)
Quantifiable outcome
- Revenue growth of 94% year-over-year to $54 million in fiscal 2023
- +4 more outcomes
Companies that use Valeo Pharma
Customer profileNamed customers5 records
Segments5 records
Ideal customer profiles1 record
Valeo Pharma technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Valeo Pharma partnerships and signals
Strategic signalPartnerships
Three partnerships are on record, tiered core and minor.
- Novartis Pharmaceuticals Canada Inc.coreValeo entered into a 7-year Commercialization and Supply Agreement with Novartis for Canadian rights to XIIDRA and SIMBRINZA ophthalmic products. Novartis has agreed to sell XIIDRA global rights to Bausch + Lomb, though SIMBRINZA is not included in the divestiture.
- Kaléo Inc.coreValeo entered into a License, Supply, and Commercialization agreement with Kaléo Inc. for Canadian rights to ALLERJECT (epinephrine injection, USP) auto-injector for treatment of serious allergic reactions.
- Veru Inc.minorValeo entered into a Commercial Services Agreement with Veru Inc. for sabizabulin in Canada, a novel dual antiviral and anti-inflammatory agent for COVID-19 treatment. Following FDA rejection of Veru's EUA request for sabizabulin, the agreement was mutually terminated in May 2023.
Scale indicators10 records
Recent moves6 records
Expansion highlights5 records
Valeo Pharma competitors and assessment
Company assessmentMarket position
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
Valeo Pharma social profiles
Digital presenceValeo Pharma financial estimates
Financial estimateRevenue estimate
Valuation estimate
Valeo Pharma leadership team
Management profileNumber of profiles
Profiles13 records
Valeo Pharma funding detail
Funding detailFunding overview
Funding rounds10 records
Investors3 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Valeo Pharma M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Valeo Pharma
What does Valeo Pharma do?
Valeo Pharma is a Canadian specialty pharmaceutical company that licenses and acquires Canadian commercial rights to innovative, proprietary prescription drugs from international pharmaceutical partners, and commercializes them through its own field sales force, marketing teams, and dedicated business units in respiratory/allergy, ophthalmology, and specialty therapeutic areas. The company's portfolio consists of 12 commercialized products, including Enerzair, Atectura, Redesca, Xiidra, Simbrinza, Allerject, and Onstryv.
Is Valeo Pharma a public or private company?
Valeo Pharma is a public company. It is classified as public and is currently operating.
When was Valeo Pharma founded?
Valeo Pharma was founded in 2003. It employs 51 to 100 people.
Where is Valeo Pharma based?
Valeo Pharma is headquartered in Kirkland, Canada, in the North America region.
How does Valeo Pharma make money?
Two revenue lines are on record. Pharmaceutical Product Sales are the primary driver. The others are working Capital and Growth Financing.
Does Valeo Pharma have an API?
No public API is recorded for Valeo Pharma.
What industry is Valeo Pharma in?
Valeo Pharma's product category is Specialty Pharmaceuticals. Its primary akta.pro industry code is HLAIAJAB, Specialty Pharmaceutical Distributors, with a secondary code of HLAIAAAH, Respiratory & Allergy Pharmaceuticals. Its NAICS code is 424210 and its SIC code is 5122.